HELP WANTED:
MARYLAND
The head of a hospital system in Maryland’s Prince George’s County, a majority black community bordering Washington, D.C., said the area’s intensive care units “are bursting at the seams.”
“I would say we are the epicenter of the epicenter,” said Dr. Joseph Wright, interim CEO of University of Maryland Capital Region Health. He said the three emergency departments his medical system operates are steadily seeing upward of 70 new COVID-19 confirmed and suspected patients every day.
“We are certainly still very much in a very busy phase of this surge,” Wright said.
Maryland Gov. Larry Hogan has announced the first stage of reopening beginning Friday evening, but Prince George’s County Executive Angela Alsobrooks said a local order would extend through June 1.
NEW MEXICO
A hospital in Gallup, New Mexico, is on the front lines of a grinding outbreak on the Navajo Nation that recently prompted a 10-day lockdown with police setting up roadblocks to discourage non-emergency shopping.
...The departure last week of the hospital’s lung specialist has limited its ability to treat COVID-19 patients, as people with acute respiratory symptoms are transported to Albuquerque, some two hours away. About 17 nurses were cut from the hospital’s workforce in March, at least 32 workers have tested positive for the virus and its intensive care unit is at capacity.
“My staff is physically exhausted, emotionally exhausted and they are suffering from moral injury,” chief nursing officer Felicia Adams said.
Both:
AP News Service
https://www.msn.com/en-us/news/world/virus-hot-spots-flare-hospitals-tested-as-economies-reopen/ar-BB146Z4K?ocid=spartanntp
“...an interesting and potentially clinically important finding in the study by de Abajo and colleagues is that the use of RAAS inhibitors compared with other antihypertensive drugs almost halved the risk of adverse outcomes in patients with COVID-19 who had diabetes (adjusted OR 0·53, 95% CI 0·34–0·80).4 Other studies have also suggested that use of RAAS inhibitors might confer protective effects against complications and death in patients with COVID-19 versus other antihypertensive drugs, although these studies were not restricted to patients with diabetes.9, 10
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31131-4/fulltext
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31030-8/fulltext
protective effect of RAAS (ace2) inhibitors with Diabetic Covid patients